$CETY

Clean Energy Technologies, Inc. (CETY): Entry into a Material Definitive Agreement

Clean Energy Technologies, Inc. (CETY) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01. Entry into a Material Definitive Agreement. Effective July 29, 2026, Clean Energy Technologies, Inc. (the “ Company ”) entered into a securities purchase agreement (the “ 1800 SPA ”) with 1800 Diagonal Lending LLC, a Virginia limited liability company (“ 1800 Diagonal

Original reporting
Published Jul 31, 2026, 9:15 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 31, 2026, 9:16 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefCorporate actions
Primary signal
$CETY
Neutral
medium confidence
Mentioned
$CETY
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$CETYNeutralMed
01

Why it matters

Traders should focus on liquidity and dilution/credit risk from the note’s payment schedule, default interest (22%), and event-of-default provisions tied to conversion and share issuance.

02

Market read

This is a fresh, company-specific financing disclosure with concrete cash payment terms and default/conversion mechanics that can move risk perception.

03

What to watch

Key economic impact depends on whether the note is convertible in practice, how often defaults are likely, and whether proceeds fund revenue-generating projects versus near-term obligations.

Relevance 6/10Novelty 7/10Timing: filed after-hours on 2026-07-31, for next-session trading

Background

The SEC 8-K reports CETY’s entry into a material definitive agreement, including issuance of a promissory note and related unregistered equity sale mechanics.

Company-level read

Ticker impact

$CETYNeutralMedium confidence
Context

CETY disclosed an 8-K entry into a material definitive agreement, including a $147,840 promissory note with monthly payments and default terms.

Expected impact

Near-term sentiment likely neutral to negative, with volatility tied to execution risk and potential dilution if conversion is triggered.

Evidence & confidence

The note specifies interest, monthly payment schedule, event-of-default triggers, and conversion-related obligations, which can affect perceived credit risk and equity dilution risk.

Market effects

Adds to the broader risk picture for small-cap clean-energy financings that rely on structured notes and potential equity conversion.

No clear regional spillover beyond US microcap credit/dilution risk.

Limited global relevance; primarily company-specific financing terms.

Counterpoint

The note includes a right to prepay and an acceleration/prepayment framework, which could reduce long-term overhang if CETY can refinance quickly.

Key entities

  • Clean Energy Technologies, Inc.

    Nevada corporation filing the 8-K and issuing the promissory note under a securities purchase agreement.

  • 1800 Diagonal Lending LLC

    Virginia LLC holder/payee under the $147,840 promissory note.

Related articles

$ABTHigh

Abbott Plans to Separate Nutrition Business Into Publicly Traded Company by End of 2027

Abbott Laboratories (ABT) plans to spin off its Nutrition division, generating $8.5B in annual revenue, into a separate publicly traded company by the end of 2027. The move, subject to approvals, will allow Abbott to focus on medical devices, diagnostics, and pharmaceuticals, with the new company led by Daniel Salvadori. Existing shareholders will receive shares in both entities, and the transaction is not expected to affect Abbott's 2026 or 2027 financial guidance.

$ABTMed

Abbott Stock Falls 4% on Similac Spinoff: It’s Shedding Its Slowest Business, but Who Keeps the Lawsuits?

Abbott Laboratories (ABT) shares dropped 4% after announcing plans to spin off its Nutrition business, including Similac, by 2027. The unit generates $8.5B annually but has shown minimal growth. The move leaves Abbott with a medical device and diagnostics business, with $42B in annual sales. The company expects to maintain its 2026 guidance and current dividend payouts. Daniel Salvadori will lead the new nutrition company.

$UDRHigh

UDR, Apollo form $2B joint venture

UDR and Apollo are forming a $2B joint venture for 19 apartment properties. Apollo will invest $1.34B for a two-thirds stake, while UDR retains one-third and will manage the portfolio. UDR plans to use proceeds for high-growth assets, debt reduction, and corporate purposes. The transaction implies a 6% cap rate and is expected to close on Oct. 29.

$ABTHighAI 8/10

Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company

ABBOTT LABORATORIES (ABT) filed an SEC Form 8-K — Other Events. Exhibit 99.1 Abbott announces its intention to separate its global Nutrition business into an independent, publicly traded company • Separation will unlock potential of both companies to pursue distinct growth and value-creation strategies • The new Nutrition company will be a gl

$ABTMed

Abbott to Carve Out Nutrition Business Into Independent Company -- 2nd Update

Abbott Laboratories plans to separate its nutrition business, with $8.5B in annual sales, into an independent company by 2027. The move aims to focus on higher-growth areas. Shares fell 4% premarket. Q3 sales rose 14% to $13.01B, but profit declined due to higher costs. Abbott faces ongoing litigation over its baby-formula facility and has agreed to multimillion-dollar settlements.